Brought to you by 
NeoGenomics acquires Clarient for $277mm in cash and stock
29 Sep 2020
Executive Summary
NeoGenomics Inc. is paying $277mm in cash and stock to buy Clarient Inc. and Clarient Diagnostics Services Inc. from GE Healthcare. The acquired companies bring a strong base of pathology services for solid tumor analysis, including testing for breast, colon, and lung cancers, as well as a $20mm clinical trial services business.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Cytology
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeoGenomics acquires Clarient for $277mm in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice